|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1258217456 |
| 003 |
OCoLC |
| 005 |
20231120010550.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
210701s2021 enk o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d K6U
|d SFB
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780128236857
|q (electronic bk.)
|
| 020 |
|
|
|a 012823685X
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128236840
|
| 020 |
|
|
|z 0128236841
|
| 035 |
|
|
|a (OCoLC)1258217456
|
| 050 |
|
4 |
|a RC271.C5
|
| 082 |
0 |
4 |
|a 616.994061
|2 23
|
| 245 |
0 |
0 |
|a Epigenetic regulation in overcoming chemoresistance /
|c edited by Chunfu Wu and Lihui Wang.
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2021.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Cancer sensitizing agents for chemotherapy ;
|v 15
|
| 505 |
0 |
|
|a Intro -- Epigenetic Regulation in Overcoming Chemoresistance -- Copyright -- Cover Image Insert -- Aims and Scope for Series ``Cancer Sensitizing Agents for Chemotherapy�� -- About the Series Editor -- Aims and Scope of the Volume -- About the Volume Editors -- Preface -- Contents -- Contributors -- Chapter 1: The role of epigenetic regulation in cancer -- Introduction -- DNA methylation -- Histone modification -- RNA regulation -- Conclusion -- References -- Chapter 2: DNA methyltransferase inhibitors (DNMTis) as sensitizing agents to overcome chemoresistance -- Aberrant DNA methylation in cancer -- Deregulation of DNA methyltransferases in cancer -- DNA methyltransferase inhibitors (DNMTis) in cancer therapy -- DNMTi as sensitizing agents for chemotherapy -- Global aberrant DNA methylation induces chemoresistance -- Regional DNA hypermethylation induces chemoresistance -- Antiapoptosis proteins and proliferation-related genes -- DNA damage repair proteins -- Drug-target interactions -- PI3K/Akt pathway -- MicroRNAS -- Combination of DNMTis with other therapies -- Conclusions and prospects -- Acknowledgments -- References -- Chapter 3: Histone deacetylase inhibitors (HDACi), the ongoing epigenetic agents to enhance chemotherapy sensitization -- Introduction -- Classification and application of HDACi -- Hydroxamic acids as HDACi -- Cyclic peptides as HDACi -- Short-chain fatty acids as HDACi -- Benzamides as HDACi -- Other HDACi -- HDACi enhance chemotherapy sensitization -- HDACi enhance sensitization in nonsmall cell lung cancer -- HDACi enhances sensitization in breast cancer -- HDACi enhance sensitization in prostate cancer -- HDACi enhance sensitization in gastric cancer -- HDACi enhance sensitization in liver cancer -- HDACi enhance sensitization in multiple myeloma cells -- Summary -- References.
|
| 505 |
8 |
|
|a Chapter 4: Histone lysine demethylase inhibitor (HDMi) as chemo-sensitizing agent -- The nature of histone modifications -- The dynamics of histone methylation -- Histone lysine demethylases -- Dysregulation of KDMs in cancers -- Aberrant KDMs and chemoresistance -- KDM1/LSD inhibitors as chemo-sensitizing agents -- JmjC demethylase inhibitors as chemo-sensitizing agents -- Concluding remarks -- Acknowledgment -- References -- Chapter 5: Targeting histone lysine methyltransferases for drug sensitization -- An overview of histone methylation -- Histone lysine methyltransferases -- Dysregulation of KMTs in cancers -- Targeting EZH2 for drug sensitization -- G9a, DOT1L, and other KMTs in drug sensitization -- Conclusion and outlook -- Acknowledgments -- References -- Chapter 6: Ribonucleotide base-modifying enzymes and diseases -- Introduction -- Guanine-modification enzymes -- METTL1 -- MRM3 -- TRMT10A -- TRMT10C -- Cytosine-modification enzymes -- DNMT2 -- NAT10 -- Uridine-modification enzymes -- ALKBH8 -- PUS1 -- Adenine-modification enzymes -- TRMT61B -- METTL3 -- FTO -- ALKBH5 -- Conclusion -- Acknowledgments -- References -- Chapter 7: The combination strategy with epigenetic therapy, chemotherapy, and immunotherapy -- Introduction -- Epigenetic therapy combining with chemotherapy -- Combination of HDAC inhibitors and chemotherapy -- Combination of BET inhibitors and chemotherapy -- Combination of EZH2 inhibitors and chemotherapy -- Combination of LSD1 inhibitors and chemotherapy -- Combination of DNMT inhibitors and chemotherapy -- Epigenetic therapy combining with immunotherapy -- Combination of HDAC inhibitors and immunotherapy -- Combination of BET inhibitors and immunotherapy -- Combination of EZH2 inhibitors and immunotherapy -- Combination of LSD1 inhibitors and immunotherapy -- Conclusion and prospect -- References.
|
| 505 |
8 |
|
|a Chapter 8: Future epigenetic treatment strategies -- Introduction -- The promising epigenetic therapy -- New approaches for epigenetic therapy -- The therapies targeting ncRNA -- miRNA in chemoresistance -- Epigenetic therapies targeting miRNA -- Nanostructured carriers -- Bioactive compounds and Chinese herbal compounds -- The lncRNA in chemoresistance -- Epigenetic therapies targeting lncRNA -- Nanostructured carriers -- Bioactive compounds and Chinese herbal compounds -- The predictive biomarkers -- The dawn and shortage of predictive biomarkers -- The discovering of epigenetic biomarkers -- Combination with targeted therapy -- EGFR-TKIs -- Antiangiogenic agents -- PI3K/AKT/mTOR pathway inhibitors -- Conclusion -- References -- Index.
|
| 650 |
|
0 |
|a Drug resistance in cancer cells.
|
| 650 |
|
0 |
|a Epigenetics.
|
| 650 |
|
2 |
|a Drug Resistance, Neoplasm
|0 (DNLM)D019008
|
| 650 |
|
6 |
|a Cellules canc�ereuses
|x R�esistance aux m�edicaments.
|0 (CaQQLa)201-0217335
|
| 650 |
|
6 |
|a �Epig�en�etique.
|0 (CaQQLa)000270630
|
| 650 |
|
7 |
|a Drug resistance in cancer cells
|2 fast
|0 (OCoLC)fst00898703
|
| 650 |
|
7 |
|a Epigenetics
|2 fast
|0 (OCoLC)fst01893642
|
| 700 |
1 |
|
|a Wu, Chunfu.
|
| 700 |
1 |
|
|a Wang, Lihui.
|
| 776 |
0 |
8 |
|i Ebook version :
|z 9780128236857
|
| 776 |
0 |
8 |
|i Print version:
|t Epigenetic regulation in overcoming chemoresistance.
|d London : Academic Press, 2021
|z 0128236841
|z 9780128236840
|w (OCoLC)1164504687
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128236840
|z Texto completo
|
